Dr. Martens saw its group revenue increase by 3% year-on-year in the 13 weeks to 29 December 2024 to £267m, after making "good progress" in turning around its performance in the US market.

In the Americas, the British shoe brand saw its direct to consumer (DTC) revenue increase by 4%, in line with its plan to return to positive growth in the second half of its financial year.

Furthermore, its APAC DTC revenue increased by 17%, driven by an increase in e-commerce sales. Its largest market in APAC, Japan, continued to "deliver good growth", with a "strong performance" across the region.

Despite these increases, EMEA DTC revenue dropped by 5% year-on-year, with Dr. Martens stating that this was "impacted by the deep promotional nature of several markets, especially in December".

The figures come as Ije Nwokorie was promoted from the role of chief brand officer to chief executive officer (CEO) at the group.

Nwokorie stated: "I am excited to be CEO of Dr. Martens. The global relevance of our iconic brand, the strength of our product line and the passionate commitment of our team give me great confidence for FY25 and beyond.

"Our Q3 trading was as expected. We have made good progress against our objective of turning around our USA performance, with USA DTC in positive growth in Q3."

Looking ahead, the firm said that its outlook for the current 2025 financial year is unchanged and its remains on track to achieve its objectives for the year.

Investment director at AJ Bell, Russ Mould, concluded: "The company’s big focus has been on improving the performance of its US DTC business and restoring its revenue to positive growth in the second half. On a constant currency basis, it is on track to do so but the company doesn’t spell out if this is the case without this adjustment. Reading between the lines it likely isn’t, based on the disparity between the reported figure and constant currency figure for the Americas as a whole.

"In the EMEA region, Dr. Martens’ showing is weak whatever way you want to spin it – although the company may have done its bit to protect brand integrity by not engaging in heavy discounting around Christmas.

"Performance is improving on a dismal first half of the year and the company remains on track to hit its guidance for the full year. While this statement is not a total disaster it will be unlikely to win over many sceptics. Dr. Martens still has a big job on its hands to rebuild its credibility with the market."

---